FIELD: medicine, pharmacy.
SUBSTANCE: group of inventions refers to pharmacy. A combination for cancer treatment, comprising bendamustine or pharmaceutically acceptable salt thereof and an HDAC inhibitor. Compound 1, or pharmaceutically acceptable salt thereof is used as the HDAC inhibitor. Application of the said composition for cancer treatment is also described.
EFFECT: invention provides implementation of the specified purpose (compound 1).
10 cl, 13 dwg, 17 ex, 13 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| NEW MODE OF RECEPTION OF N-HYDROXY-4-{2-[3-(N,N-DIMETHYLAMINOMETHYL)BENZOFURAN-2-ILCARBONYLAMINO]ETHOXY} BENZAMIDE | 2012 |
|
RU2600793C2 |
| METHODS FOR CANCER TREATMENT USING AUTOPHAGY INHIBITOR BASED ON THIOXANTHONE | 2011 |
|
RU2627588C2 |
| METHODS OF TREATING VIRUS-ASSOCIATED FORMS OF CANCER WITH HISTONE DEACETYLASE INHIBITORS | 2020 |
|
RU2819782C2 |
| COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | 2016 |
|
RU2759963C2 |
| METHOD OF FINAL DIFFERENTIATION INDUCTION | 2010 |
|
RU2530648C2 |
| METHODS OF INFLUENCING TRANSCRIPTION CONTROL IN SUPER-ENHANCER AREAS | 2015 |
|
RU2737508C2 |
| METHOD OF INDUCTION OF TERMINAL DIFFERENTIATION | 2003 |
|
RU2320331C2 |
| METHOD OF INDUCING TERMINAL DIFFERENTIATION | 2003 |
|
RU2394022C2 |
| COMBINATION OF A HISTONE DEACETYLASE INHIBITOR AND A PROTEIN KINASE INHIBITOR AND PHARMACEUTICAL APPLICATION THEREOF | 2019 |
|
RU2770754C1 |
| COMBINED THERAPY WITH EZH2 INHIBITOR | 2018 |
|
RU2754131C1 |
